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Receptor interacting protein kinase 1 (RIPK1) regulates cell death and inflammatory responses
downstream of TNFR1 and other receptors, and has been implicated in the pathogenesis of
inflammatory and degenerative diseases. RIPK1 kinase activity induces apoptosis and
necroptosis, however the mechanisms and phosphorylation events regulating RIPK1-
dependent cell death signaling remain poorly understood. Here we show that RIPK1 autop-
hosphorylation at serine 166 plays a critical role for the activation of RIPK1 kinase-dependent
apoptosis and necroptosis. Moreover, we show that S166 phosphorylation is required for
RIPK1 kinase-dependent pathogenesis of inflammatory pathologies in vivo in four relevant
mouse models. Mechanistically, we provide evidence that trans autophosphorylation at S166
modulates RIPK1 kinase activation but is not by itself sufficient to induce cell death. These
results show that S166 autophosphorylation licenses RIPK1 kinase activity to induce down-
stream cell death signaling and inflammation, suggesting that S166 phosphorylation can serve
as a reliable biomarker for RIPK1 kinase-dependent pathologies.
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Receptor interacting protein kinase 1 (RIPK1) has emergedas a key player regulating cell death and inflammation,which is implicated in the pathogenesis of inflammatory
and degenerative diseases1,2. RIPK1 regulates signaling down-
stream of tumor necrosis factor receptor 1 (TNFR1) as well as toll
like receptors (TLR) 3 and 4, by exhibiting both kinase activity-
dependent and -independent functions. Studies in RIPK1-
deficient mice and cells showed that RIPK1 acts as a scaffold
independently of its kinase activity to regulate pro-inflammatory
and pro-survival TNFR1 and TLR3/4 signaling, a function that is
essential for mouse development and tissue homeostasis3–10. In
contrast, RIPK1 kinase activity induces cell death by activating
either caspase-8-dependent apoptosis or RIPK3-mixed lineage
kinase like (MLKL)-dependent necroptosis1,2,11,12. Multiple stu-
dies using genetic or pharmacological inhibition have identified
RIPK1 kinase activity-dependent cell death as a potent trigger of
inflammation in different tissues13–17. Furthermore, RIPK1
kinase activity emerged as driver of ischemic injury18–20 as well as
neurodegenerative diseases such as multiple sclerosis (MS)21, ALS
(amyotrophic lateral sclerosis)22 and Alzheimer’s disease23. These
studies identified RIPK1 kinase activity as a key factor con-
tributing to the pathogenesis of inflammatory diseases, prompting
the development of RIPK1 kinase inhibitors24–28 that reached
clinical trials for the treatment of inflammatory and neurode-
generative diseases as well as pancreatic cancer24,25.
The critical role of RIPK1 in driving cell death and inflam-
mation motivated several studies addressing the mechanisms
regulating its cytotoxic and pathogenic potential. Recent studies
reported that RIPK1 phosphorylation by a number of kinases,
including inhibitor of NF-κB (IκB) kinases (IKKs), mitogen
activated protein kinase (MAPK)-activated protein kinase 2
(MK2), transforming growth factor beta activating kinase 1
(TAK1), as well as TANK-binding kinase 1 (TBK1) and IKKε,
limits TNF-induced RIPK1 kinase-dependent cell death and
inflammation in vitro and in vivo22,29–35. These results revealed
that RIPK1 kinase activity is tightly controlled by a multitude of
mechanisms, consistent with its strong cytotoxic potential.
Despite the well-established role of RIPK1 kinase activity in
driving cell death and inflammatory pathologies, it remains
unclear how RIPK1 kinase activity regulates downstream signal-
ing. Although RIPK1 was also proposed to phosphorylate other
substrates such as DRP1 (ref. 36), autophosphorylation is cur-
rently considered the main and critical function of RIPK1 kinase
activity. Several autophosphorylation sites have been detected in
mouse RIPK1, including serine residues 14/15, 161 and 166, as
well as threonine 169 (refs. 13,32,37,38), while autophosphorylation
at serines 14/15, 20, 161 and 166 was reported for human RIPK1
(ref. 37). The currently prevailing model is that autopho-
sphorylation induces conformational changes in RIPK1 that allow
its association with cell death effectors including fas-associated
with death domain (FADD) and RIPK3, facilitating the formation
of cell death-inducing signaling complexes causing apoptosis or
necroptosis39. However, the role of specific autophosphorylation
events and the mechanisms by which these trigger cell death
remain poorly understood. Using in vitro cellular systems, two
independent studies reported that alanine substitution at S161
leads to a reduction in RIPK1 kinase activity37,40. More recently,
phosphorylation at S161 was proposed to promote an “open
conformation” of the T-loop, thereby facilitating RIPK1-RIPK3
interaction to promote cell death38, suggesting a major functional
importance of S161. Apart from S161, none of the other residues
seemed to have a major effect on cell death induction40. While
RIPK1 autophosphorylation at S166 is commonly employed as a
biomarker of RIPK1 kinase activity10,21,35,41, the functional role
and mechanism of action of this autophosphorylation site
remains elusive.
Here we identified RIPK1 autophosphorylation at S166 as a
critical event for RIPK1-mediated apoptosis and necroptosis.
Importantly, we show that S166 phosphorylation is essential for
the pathogenesis of RIPK1-mediated inflammatory conditions
in vivo in four relevant mouse models of inflammation.
Mechanistically, we provide evidence that S166 phosphorylation
regulates the kinase activity of RIPK1, but is not sufficient by itself
to impose the conformational changes of RIPK1 that are required
for the activation of downstream cell death signaling.
Results
S166 autophosphorylation drives RIPK1-dependent cell death.
To address the role of RIPK1 autophosphorylation in the reg-
ulation of RIPK1-mediated cell death and inflammatory respon-
ses, we generated knock-in mice expressing RIPK1 with
substitution of serine at position 166 with alanine (RIPK1S166A
mutation) from the endogenous Ripk1 genomic locus (Supple-
mentary Fig. 1a). Ripk1S166A/S166A mice were born at the expected
Mendelian frequency and reached adulthood without showing
signs of pathology, demonstrating that inhibition of RIPK1
phosphorylation at S166 does not interfere with normal mouse
development and homeostasis under steady state conditions.
Immunoblot analysis of bone marrow derived macrophages
(BMDMs) from Ripk1S166A/S166A mice showed that the mutated
RIPK1S166A protein was expressed at similar levels as wild-type
(WT) RIPK1 (Supplementary Fig. 1b, c). Moreover, Ripk1S166A/
S166A BMDMs showed normal activation of NF-κB and MAPK
signaling in response to TNF or LPS stimulation (Supplementary
Fig. 1b, c), as well as normal LPS-induced expression of NF-κB-
dependent genes (Supplementary Fig. 1d). The recruitment and
ubiquitination of RIPK1 within the TNFR1 signaling complex
(often referred to as complex I) regulates pro-inflammatory and
pro-survival signaling42. In order to determine whether S166A
mutation affects RIPK1 recruitment and ubiquitination in com-
plex I, we stimulated BMDMs with FLAG-tagged hTNF and
immunoprecipitated the activated TNFR1 using anti-FLAG
antibodies. Immunoblot analysis revealed that the S166A muta-
tion did not affect the recruitment and ubiquitination of RIPK1 in
complex I (Fig. 1a). Overall, these results suggest that the S166A
mutation did not affect the scaffolding functions of RIPK1 that
regulate proinflammatory signaling and tissue homeostasis.
We then asked whether autophosphorylation at S166 plays a
role in RIPK1 kinase-dependent cell death downstream of
TNFR1. We thus treated BMDMs as well as dermal and lung
fibroblasts from WT, Ripk1S166A/S166A and Ripk1D138N/D138N
mice, which express catalytically inactive RIPK1 (ref. 43), with
TNF in combination with the SMAC-mimetic compound
birinapant (S) and the pan-caspase inhibitor Z-VAD-FMK (Z)
to induce necroptosis13,43. Assessment of cell death with IncuCyte
real-time imaging revealed that the RIPK1S166A mutation
considerably protected cells from TSZ-induced necroptosis
(Fig. 1b–d). Under the same conditions, inhibition of RIPK1
kinase activity either genetically in Ripk1D138N/D138N cells or
pharmacologically by treatment with Necrostatin-1s (Nec1s)
strongly prevented necroptosis (Fig. 1b–d). To assess whether
S166 phosphorylation is also critical for TNF-induced apoptosis
we treated dermal and lung fibroblasts with TNF in the presence
of birinapant (TS). Ripk1S166A/S166A dermal and lung fibroblasts
were partially protected from TS-induced death (Fig. 1e, f),
suggesting that S166 phosphorylation is important also for the
induction of RIPK1-mediated apoptosis. Of note, RIPK1S166A
mutation did not prevent cell death induced by TNF in the
presence of cycloheximide (C) in lung fibroblasts, which was
also not affected by inhibition of RIPK1 kinase activity in
Ripk1D138N/D138N cells or by Nec-1s treatment as previously
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reported44 (Fig. 1g). We then assessed the role of S166
phosphorylation in LPS or poly(I:C)-induced necroptosis by
measuring cell death of BMDMs in response to treatment with
LPS+ Z-VAD-FMK (LZ) or poly(I:C)+ Z-VAD-FMK (PZ),
respectively. As shown in Fig. 1h, i, Ripk1S166A/S166A BMDMs
were partially protected from LZ- and PZ-induced necroptosis
compared to WT cells, as opposed to Ripk1D138N/D138N or Nec-
1s-treated BMDMs that were fully protected. Taken together, our
results showed that abolishing autophosphorylation at S166 did
not affect RIPK1 scaffolding functions regulating the activation of
pro-inflammatory and pro-survival NF-κB and MAPK signaling,
but considerably inhibited RIPK1 kinase activity-dependent cell
death downstream of TNFR1, TLR3 and TLR4.
S166 phosphorylation facilitates necrosome formation. To
investigate how absence of phosphorylation at S166 impairs
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RIPK1 kinase activity-dependent cell death, we assessed the for-
mation of the RIPK1-dependent necroptosis-inducing signaling
complex known as complex IIb or necrosome. Therefore, we
treated BMDMs with TSZ and analyzed the interaction of RIPK1
with FADD and caspase-8 by immunoprecipitating RIPK1 with
specific antibodies followed by immunoblotting. In WT BMDMs,
we detected strong association of RIPK1 with FADD and caspase-
8 two and four hours after TSZ treatment, concurrent with RIPK1
phosphorylation at S166 and cleavage of caspase-8 (Fig. 2a). In
Ripk1S166A/S166A cells on the other hand, we did not observe
association of RIPK1 with FADD or with caspase-8 (Fig. 2a),
suggesting that loss of autophosphorylation at S166 strongly
inhibited the ability of RIPK1 to nucleate the formation of the
necrosome.
Necroptosis relies on MLKL phosphorylation by RIPK3 and
the subsequent assembly of MLKL oligomers that translocate to
the plasma membrane to execute cell lysis45,46. To determine
whether RIPK1 autophosphorylation at S166 is required for
MLKL oligomer formation upon necroptotic cell death induction,
we analyzed whole cell lysates from TSZ-treated WT, Ripk1S166A/
S166A and Ripk1D138N/D138N BMDMs under non-reducing condi-
tions by immunoblotting with anti-MLKL antibodies. Whereas a
high molecular weight MLKL band was detected in WT cells 4 h
after TSZ stimulation, this shift was absent in Ripk1S166A/S166A
and also Ripk1D138N/D138N cells (Fig. 2b). Similarly, S166A
mutation strongly inhibited phosphorylation and oligomerization
of MLKL in response to LZ and PZ treatment (Fig. 2c, d).
Collectively, these results showed that RIPK1 autophosphoryla-
tion at S166 is critical for necrosome formation and MLKL
activation in response to TSZ, LZ and PZ stimulation.
S166A mutation prevents RIPK1-dependent colitis. To inves-
tigate whether autophosphorylation at S166 regulates RIPK1-
mediated cell death also in vivo, we assessed the effect of the
S166A mutation in mouse models of inflammation caused by
RIPK1 kinase activity-dependent cell death. Mice with intestinal-
epithelial cell (IEC)-specific ablation of NEMO (NEMOIEC-KO)
spontaneously develop severe colitis, which is caused by TNF-
induced RIPK1 kinase-dependent death of IECs15,47. We there-
fore crossed NEMOIEC-KO with Ripk1S166A/S166A mice to inves-
tigate whether RIPK1 autophosphorylation at S166 plays a role in
driving the intestinal pathology. Immunohistological analysis of
colonic sections from 11-week-old mice revealed severe intestinal
pathology in NEMOIEC-KO mice, characterized by epithelial
thickening, ulcer formation and immune cell infiltration into the
colonic mucosa and submucosa, as well as an increased number
of apoptotic IECs detected by immunostaining against cleaved
caspase-3 (CC3) (Fig. 3a–d), as previously reported15. In contrast,
analysis of colon sections from NEMOIEC-KO Ripk1S166A/S166A
mice revealed a largely normal architecture without signs of IEC
death and mucosal inflammation (Fig. 3a–d). Moreover, whole
genome microarray gene expression analysis of colonic RNA
confirmed that the Ripk1S166A/S166A mutation prevented colon
inflammation in NEMOIEC-KO mice. Specifically, the gene
expression profile of NEMOIEC-KO Ripk1S166A/S166A was similar
to NemoFL mice as opposed to the profile of NEMOIEC-KO mice,
which showed altered expression of a number of genes including
several inflammatory cytokines and chemokines such as Tnf, Ccl5,
Cxcl1 and Il1b (Fig. 3e, f). The protective effect of the S166A
mutation was comparable to that offered by the kinase inactive
RIPK1D138N mutation15, showing that autophosphorylation at
S166 is essential for RIPK1 kinase activity-dependent IEC death
and colitis development in NEMOIEC-KO mice.
S166A mutation prevents RIPK1-dependent hepatitis and
cancer. Mice with liver parenchymal cell (LPC)-specific NEMO
deficiency (NEMOLPC-KO) spontaneously develop steatohepatitis
and hepatocellular carcinoma (HCC), which is driven by RIPK1
kinase-dependent hepatocyte apoptosis14,48,49. We assessed the
role of S166 phosphorylation in the development of the liver
pathology by crossing the NEMOLPC-KO mice with Ripk1S166A/
S166A animals. As shown previously14,48,49, NEMOLPC-KO mice
presented with elevated alanine aminotransferase (ALT) levels in
the serum at the age of 8 weeks, indicative for liver damage
(Fig. 4a). In contrast, NEMOLPC-KO Ripk1S166A/S166A mice
showed strongly reduced serum ALT levels at this age, indicating
that abolishing autophosphorylation at S166 prevented liver
damage in NEMOLPC-KO mice similarly to the lack of RIPK1
kinase activity14. Immunohistochemical analysis of liver sections
from 8-week-old NEMOLPC-KO Ripk1S166A/S166A mice revealed
that loss of S166 phosphorylation strongly prevented apoptosis
and compensatory proliferation of hepatocytes, hepatic stellate
cell activation and macrophage infiltration (Fig. 4b), consistent
with the reduced serum ALT levels in these mice. Furthermore,
analysis of livers from 50-week-old mice showed that the
RIPK1S166A mutation prevented liver tumor development in
NEMOLPC-KO mice (Fig. 4c–f). Thus, RIPK1 autopho-
sphorylation at S166 is essential for RIPK1 kinase activity-
dependent hepatocyte apoptosis, chronic hepatitis and HCC
development in NEMOLPC-KO mice.
S166A mutation prevents RIPK1-dependent skin inflamma-
tion. Intrigued by the findings that the S166A mutation pre-
vented cell death and inflammation induced by NEMO deficiency
in IECs and hepatocytes, we sought to examine the effect of this
mutation in other in vivo models of RIPK1 kinase-dependent
Fig. 1 S166 phosphorylation drives RIPK1-dependent cell death. a BMDMs from mice of the indicated genotypes were treated with FLAG-hTNF for 0 or 5
min and FLAG-immunoprecipitates were analyzed with the indicated antibodies. Representative data of two independent experiments is shown. b BMDMs
from mice of the indicated genotypes were treated with a combination of TNF (T; 10 ngml−1), Z-VAD-FMK (Z) and SMAC mimetic (S (Birinapant); 1 µM)
in the presence or absence of Nec-1s. c Primary dermal fibroblasts from mice of the indicated genotypes were treated with combinations of TNF (T; 20 ng
ml−1), Z-VAD-FMK (Z) and SMAC mimetic (S (Birinapant); 1.5 µM) in the presence or absence of Nec1s. d Primary lung fibroblasts from mice of the
indicated genotypes were treated with combinations of TNF (T; 20 ngml−1), Z-VAD-FMK (Z) and SMAC mimetic (S (Birinapant); 1 µM) in the presence or
absence of Nec-1s. e Primary dermal fibroblasts from mice of the indicated genotypes were treated with combinations of TNF (T; 20 ngml−1) and SMAC
mimetic (S (Birinapant); 1.5 µM) in the presence or absence of Nec-1s. f Primary lung fibroblasts from mice of the indicated genotypes were treated with
combinations of TNF (T; 20 ngml−1) and SMAC mimetic (S (Birinapant); 1 µM) in the presence or absence of Nec-1s. g Primary lung fibroblasts from mice
of the indicated genotypes were treated with TNF (20 ngml−1) in the presence or absence of cycloheximide (CHX, 1 μg ml−1) and Nec1-s. h BMDMs were
treated with LPS (L; 100 ngml−1) and Z-VAD-FMK (Z) in the presence or absence of Nec-1s. i BMDMs were treated with Poly(I:C) (P; 0.5 μg ml−1) and Z-
VAD-FMK (Z) in the presence or absence of Nec-1s. b–i Cell death was measured using an IncuCyte as described. Graphs represent four independent
experiments in b, d, f and h; three independent experiments in c, e and i and two independent experiments in g. Source data for b–i are provided as a source
data file.
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pathology. SHARPIN-deficient chronic proliferative dermatitis
mice (Sharpincpdm/cpdm) spontaneously develop severe chronic
inflammatory skin lesions, accompanied by multi-organ
inflammation50,51. The skin lesions in Sharpincpdm/cpdm mice
were previously shown to be driven by TNF-induced FADD-,
TRADD- and caspase-8- dependent keratinocyte apoptosis52,53,
which required RIPK1 kinase activity13. We generated Shar-
pincpdm/cpdm Ripk1S166A/S166A mice and found that they were
fully protected from skin inflammation at least up to the age of
40 weeks, similarly to Sharpincpdm/cpdm Ripk1D138N/D138N mice, in
contrast to Sharpincpdm/cpdm mice that developed inflammatory
skin lesions between 15–17 weeks of age (Fig. 5a, b). Histological
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analysis of skin sections from Sharpincpdm/cpdm Ripk1S166A/S166A
mice confirmed that the S166A mutation fully prevented kerati-
nocyte apoptosis, epidermal hyperplasia and skin inflammation,
similarly to Sharpincpdm/cpdm Ripk1D138N/D138N mice (Fig. 5c).
Furthermore, both the Ripk1D138N/D138N and the Ripk1S166A/S166A
mutations prevented the upregulation of the mRNA expression of
pro-inflammatory cytokines, including Tnf, Il-6, IL-1β, Ccl3 and
Cxcl3 in the skin of Sharpincpdm/cpdm mice (Fig. 5d). In addition,
liver and lung inflammation in Sharpincpdm/cpdm mice was also
inhibited by S166A mutation (Fig. 5e). Thus, RIPK1 autopho-
sphorylation at S166 drives RIPK1 kinase activity-dependent
TNFR1-mediated keratinocyte apoptosis and skin inflammation,
as well as multi-organ inflammation in Sharpincpdm/cpdm mice.
S166A mutation protects mice from TNF-induced SIRS.
Injection of a high dose of TNF in mice triggers an acute response
often described as systemic inflammatory response syndrome
(SIRS), which manifests with hypothermia and increased
expression of cytokines and chemokines in the serum and ulti-
mately results in the death of the animals16. Previous studies
showed that TNF-induced lethality is strongly prevented by
RIPK3 deficiency as well as by genetic or pharmacological inhi-
bition of RIPK1 kinase activity10,16. Moreover, TNF-induced
lethality was partially ameliorated by MLKL deficiency but fully
prevented by combined knockout of MLKL and caspase-8
(ref. 20), suggesting that acute TNF injection drives systemic
pathology by inducing both MLKL-dependent necroptosis and
caspase-8-mediated apoptosis. To assess whether RIPK1 autop-
hosphorylation at S166 regulates RIPK1-mediated systemic
pathology in response to acute TNF administration, we injected
Ripk1S166A/S166A and WT littermate mice with 500 μg/kg murine
TNF intravenously and followed their responses. TNF injection
induced the characteristic drop in body temperature in WT mice
(Fig. 6a) and resulted in the death of 70% of the animals (Fig. 6b).
In contrast, Ripk1S166A/S166A animals were strongly protected
from TNF-induced body temperature reduction (Fig. 6a) and
lethality, with only 27% of the mice succumbing (Fig. 6b).
Therefore, autophosphorylation of RIPK1 on S166 is critically
involved in RIPK1 kinase-dependent systemic toxicity induced by
high dose TNF administration.
S166 phosphorylation enhances the kinase activity of RIPK1.
Our results revealed a critical role of RIPK1 autophosphorylation
at S166 for the induction of RIPK1 kinase-dependent cell death
and inflammation in vivo and in vitro. However, how S166
autophosphorylation affects the capacity of RIPK1 to induce cell
death remains elusive. It is generally believed that autopho-
sphorylation induces conformational changes on RIPK1, which
allow its interaction with downstream cell death inducers
including FADD and RIPK3 and the formation of cell death-
inducing signaling complexes. We reasoned that autopho-
sphorylation on S166 could affect RIPK1-mediated assembly of
cell death-inducing signaling complexes in two different ways.
One possibility is that S166 phosphorylation imposes a con-
formational change exposing the protein-protein interaction
domains of RIPK1, thus facilitating the recruitment of FADD and
RIPK3. On the other hand, it is also possible that S166 autop-
hosphorylation enhances the kinase activity of RIPK1, leading to
phosphorylation of additional residues such as serine 161 or
threonine 169 to induce the conformational changes required for
cell death signaling complex assembly.
In order to distinguish between these two possible functions of
S166 autophosphorylation, we designed an experiment allowing
to assess whether the S166A mutation affects the kinase activity of
RIPK1 and also if S166 phosphorylation is the critical step
inducing the conformational changes of RIPK1 required for the
induction of cell death. In designing this experiment, we wanted
to use the most physiological system possible, as overexpression
and reconstitution experiments in cell lines are known to often
result in artifacts. To this end, we generated Ripk1D138N/S166A
mice expressing the kinase inactive RIPK1D138N protein from
one allele and the RIPK1S166A protein from the other allele,
ensuring that both proteins are expressed at physiological levels.
In these Ripk1D138N/S166A cells, three different dimers of RIPK1
can form: RIPK1D138N and RIPK1S166A homodimers, as well
as RIPK1D138N/RIPK1S166A heterodimers (Fig. 7a). The
formation of RIPK1D138N/RIPK1S166A heterodimers allows
to assess whether RIPK1S166A exhibits altered kinase activity
by examining the phosphorylation of the RIPK1D138N protein
on S166 using specific antibodies recognizing phosphorylated
S166. We therefore stimulated BMDMs or LFs from WT,
Ripk1S166A/S166A, Ripk1D138N/S166A and Ripk1D138N/D138N animals
with TNF in the presence of Z-VAD-FMK and birinapant (TSZ)
and assessed S166 phosphorylation by immunoblotting two and
four hours after stimulation. As shown in Fig. 7b, c, strong
phosphorylation of S166 was detected in TSZ-stimulated WT cells,
which was fully abolished in cells from Ripk1D138N/D138N
and Ripk1S166A/S166A mice. Importantly, S166 phosphorylation
was detected in Ripk1D138N/S166A cells, showing that RIPK1S166A
exhibits kinase activity and can phosphorylate RIPK1D138N
(Fig. 7b, c). However, phosphorylation of S166 was strongly
reduced in cells from Ripk1D138N/S166A mice in comparison to
WT cells, suggesting that RIPK1S166A exhibits reduced kinase
activity (Fig. 7b, c). Of note, cIAP1 was non-detectable in
response to TSZ treatment, indicating that birinapant led to full
degradation of the protein (Fig. 7b). The results from this
Fig. 3 S166 phosphorylation is essential for RIPK1-dependent intestinal inflammation in NEMOIEC-KO mice. a Representative images of colon sections
from NemoFL, NEMOIEC-KO, and NEMOIEC-KO Ripk1S166A/S166A littermates stained with Hematoxylin and Eosin (H&E) or immunostained for cleaved
caspase-3 (CC3) at the age of 11 weeks. CC3 staining is shown in 20× and 40× magnification. Scale bars, 100 µm. b Graph depicting numbers of ulcers on
colon sections from NEMOIEC-KO, NemoFL and NEMOIEC-KO Ripk1S166A/S166A mice. One representative out of two independend blinded countings is shown.
Statistical significance was determined using a Kruskal-Wallis test (one-sided). c Graph depicting histology scores for inflammation, tissue damage, and
overall histopathology (total) of colon sections from NEMOIEC-KO, NemoFL and NEMOIEC-KO Ripk1S166A/S166A mice. One representative out of two
independent blinded scorings is shown. Statistical significance was determined using a Kruskal-Wallis test (one-sided). d Graph depicting percentage of
crypts containing cleaved caspase-3 (CC3) positive cells in mice of the indicated genotypes. Statistical significance was determined using a Kruskal-Wallis
test (one-sided). e Clustered heat maps showing whole genome microarray analysis of gene expression in colons from NemoFL, NEMOIEC-KO and
NEMOIEC-KO Ripk1S166A/S166A mice. Only genes that were differentially regulated (Fold change > 1.4999 or <−1.4999; P < 0.05) between NemoFL and
NEMOIEC-KO mice were included. The values were normalized using Z score transformation. f Clustered heat maps showing expression of 30 cytokines
that were differentially regulated (Fold change >1.4999 or <−1.4999; P < 0.05) between NemoFL and NEMOIEC-KO mice. Values of individual mice are
plotted; n= 5 per group. b–d The dots in the graphs represent individual mice. Horizontal lines indicate mean values ± s.e.m. Source data for b–d are
provided as a source data file.
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experiment, which represents an in vivo kinase assay, revealed
that RIPK1S166A exhibited kinase activity and was capable to
phosphorylate RIPK1D138N, albeit with reduced efficiency
(Fig. 7b, c).
We then wanted to address whether S166 phosphorylation is a
critical event in imposing the conformational change required for
the RIPK1-dependent assembly of the cell death complex and the
induction of cell death. If that were the case, we would expect that
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phosphorylation of RIPK1D138N at S166 would render this kinase-
inactive RIPK1 molecule capable of inducing cell death. We
therefore assessed the induction of necroptosis in BMDMs from
Ripk1D138N/S166A mice in comparison to WT, Ripk1D138N/D138N
and Ripk1S166A/S166A cells. As shown in Fig. 7d, TSZ stimulation
induced similar levels of cell death in Ripk1D138N/S166A compared to
Ripk1S166A/S166A BMDMs both in terms of kinetics and the amount
of dying cells. Importantly, Ripk1D138N/S166A BMDMs did not show
increased cell death compared to Ripk1S166A/S166A cells, despite the
fact that S166 phosphorylation was detected under these conditions.
Consistent with the cell death assay results, phosphorylation
of RIPK3 and MLKL were reduced to a similar extent in TSZ-
stimulated LFs from Ripk1D138N/S166A and Ripk1S166A/S166A
mice (Fig. 7c). Furthermore, immunoprecipitation with anti-
FADD or anti-caspase-8 antibodies and subsequent immunoblot-
ting revealed strongly impaired recruitment of RIPK1 and RIPK3 to
the necrosome in both Ripk1D138N/S166A and Ripk1S166A/S166A
BMDMs in response to TSZ stimulation (Fig. 7e, f). Taken
together, these results showed that phosphorylation of
RIPK1D138N at S166 in Ripk1D138N/S166A cells did not increase
the efficiency of necrosome formation and the induction of
necroptosis compared to Ripk1S166A/S166A cells. Our interpretation
of these findings is that autophosphorylation at S166 is not
sufficient to trigger the conformational changes required for cell
death induction by RIPK1.
S166A inhibits RIPK1 autophosphorylation at other sites.
Besides S166, mouse RIPK1 has been shown to autopho-
sphorylate at S14, S15 and S161, as well as T169 (refs. 32,37)
indicating that multiple autophosphorylation events might be
required to unfold the full cytotoxic potential of RIPK1. To
explore the impact of RIPK1S166A mutation on RIPK1 autop-
hosphorylation at other sites, we analyzed RIPK1 phosphoryla-
tion in TSZ-treated BMDMs by mass spectrometry (MS). After
phospho-peptide enrichment with titanium dioxide (TiO2) beads,
we found in total 13,547 phosphorylation sites, including 5 sites
on RIPK1. Interestingly, we measured a peptide containing
double phosphorylation at S166 and T169 (p-S166/p-T169) after
two hours of TSZ treatment in WT cells (Fig. 8a, b). This peptide
was not found in Ripk1D138N/D138N cells, therefore also T169
likely represents an autophosphorylation site. Importantly, p-
T169 was not detected in Ripk1S166A/S166A cells, suggesting that
S166 phosphorylation might be required for subsequent phos-
phorylation of T169. We detected relatively equal levels of total
RIPK1 protein as well as RIPK1 phosphorylation at S313 under
all conditions (Fig. 8a, c), indicating that phospho-peptide
enrichment was consistently efficient between the different sam-
ples. Furthermore, we detected phosphorylation of S25 of RIPK1
in all genotypes (Fig. 8d), consistent with previous studies
showing that S25 is phosphorylated by IKKs32. In addition, we
found RIPK1 to be phosphorylated at S14 (Fig. 8e), which was
previously suggested to be an autophosphorylation site37. S14
phosphorylation was detected also in Ripk1S166A/S166A cells,
although at reduced levels compared to wild-type cells (Fig. 8e).
Surprisingly, low levels of S14 phosphorylation were measured in
Ripk1D138N/D138N cells that lack RIPK1 kinase activity (Fig. 8e),
suggesting that S14 is not exclusively a RIPK1 autopho-
sphorylation site. Earlier studies reported RIPK1 autopho-
sphorylation at S161 in response to necroptotic stimuli37,38.
However within two independent experiments we did not detect
phosphorylation of S161 in TSZ-treated BMDMs, although in
these replicates as well as in a broader context of MS experiments
targeted to RIPK1, we reproducibly measured the non-
phosphorylated peptide. Collectively, these results suggest that
autophosphorylation at S166 promotes the autophosphorylation
of additional sites on RIPK1.
Discussion
RIPK1 kinase activity has emerged as a key regulator of cell death
and inflammation that contributes to the pathogenesis of
inflammatory diseases, but the mechanisms by which RIPK1
kinase activation triggers downstream signaling remain poorly
understood. Previous experiments using primarily overexpression
and reconstitution approaches in cell lines suggested that phos-
phorylation of S161 is the critical event triggering RIPK1 kinase
activity-dependent cell death38; however, the role of S166 phos-
phorylation has not been assessed. Here we identify autopho-
sphorylation at S166 as a critical event regulating RIPK1-
mediated apoptosis and necroptosis, as well as the development
of inflammatory pathologies in vivo. Our experiments in
Ripk1S166A/S166A knock-in mice revealed that abolishing phos-
phorylation at S166 prevented the development of RIPK1 kinase-
dependent skin, intestinal, liver and systemic inflammatory
pathologies in relevant mouse models. Interestingly, the S166A
mutation did not only inhibit TNF-mediated inflammation in the
Sharpincpdm/cpdm, NEMOIEC-KO and TNF-induced SIRS mouse
models, but also fully prevented liver pathology in NEMOLPC-KO
mice, which develops independently of TNFR1, Fas and
TRAILR49. Therefore, S166 phosphorylation regulates both TNF-
dependent and -independent RIPK1 kinase activity-driven
inflammatory pathologies.
Our in vitro experiments showed that cells expressing
RIPK1S166A were partially, but not completely protected from
TNF-induced apoptosis and necroptosis as well as TLR3- and
TLR4-induced necroptosis. In contrast, our in vivo studies in
three different genetic mouse models of RIPK1-mediated
pathologies showed that the S166A mutation was as effective as
the D138N mutation in preventing inflammation. Therefore,
under physiological conditions that are best modeled in vivo,
S166 phosphorylation is essential for activating the cytotoxic
potential of RIPK1. These findings also question the physiological
significance of in vitro stimulation experiments exposing cells to
high concentrations of TNF and other cytotoxic stimuli over
several hours, which are unlikely to occur in the context of a
whole organism, and argue that such results should be treated
with caution with regards to their in vivo relevance.
Our experiments provided important mechanistic insights into
the molecular function of S166 phosphorylation for the activation
Fig. 4 S166 phosphorylation is essential for RIPK1-dependent hepatitis and liver tumorigenesis in NEMOLPC-KO mice. a Graph depicting basal serum
alanine aminotransferase (ALT) levels in 8-week-old mice of the indicated genoytpes. b Representative images of liver sections from 8-week-old mice of
the indicated genotypes that were stained with H&E or immunostained with the indicated antibodies. Scale bars, 200 μm. c Representative photographs
of livers from 50-week-old mice with the indicated genotypes. Scale bar, 1 cm. d Representative images of liver sections from 50-week-old mice of the
indicated genotypes stained with H&E. Hepatocellular carcinoma (HCC) areas are outlined and marked with an asterisk. Arrow points at a small steatotic
area observed in some NEMOLPC-KO Ripk1S166A/S166A mice. Scale bars, 200 μm. e Tumor load quantification in 50-week-old mice by liver weight/
body weight (LW/BW) ratios. f Graph depicting tumor number per liver for 50-week-old mice of the indicated genotypes. a, e, f The dots in the graphs
represent individual mice. Horizontal lines indicate mean values ± s.e.m. Statistical significance was determined using one-way ANOVA. Source data for a,
e, f are provided as source data file.
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of RIPK1 kinase-dependent signaling. Using an innovative
approach for the assessment of RIPK1 kinase activity under
physiological protein concentrations within primary cells from
Ripk1D138N/S166A mice, we found that mutation of S166 inhibited,
but could not abolish, RIPK1 kinase activity. This finding suggests
that S166 autophosphorylation acts as an amplification step to
unleash the full activation of the kinase. Moreover, our results
showing that RIPK1S166A can phosphorylate RIPK1D138N on
S166 under endogenous expression levels provided experimental
evidence that RIPK1 autophosphorylation occurs in trans within
a dimer, as suggested previously based on artificial dimerization
systems22. Furthermore, our experiments in primary cells from
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Ripk1D138N/S166A mice showed that the presence of RIPK1D138N
molecules phosphorylated on S166 did not cause increased cell
death, arguing that S166 phosphorylation is not sufficient by itself
to impose the conformational changes required for RIPK1 to
engage and activate the apoptosis- and necroptosis-inducing cell
death machineries. Together, these results argue that S166
phosphorylation licenses the autophosphorylation of additional
sites on RIPK1, which are then required either individually or in
combination to facilitate the interaction of RIPK1 with down-
stream effectors and the activation of cell death.
In addition to S166, serine residues at position 14, 15 and 161 as
well as threonine at position 169 have been previously identified as
autophosphorylation sites of mouse RIPK1 (refs. 13,32,37,38).
Although autophosphorylation at S161 was identified and proposed
to have a critical role in RIPK1-mediated cell death in studies
performed in cell lines overexpressing RIPK1 constructs37,38, we did
not detect phosphorylation of endogenous RIPK1 at S161 in our
experiments. Whereas our inability to detect S161 phosphorylation
may be related to the specific experimental setup, in our assays we
clearly measured phosphorylation of S14, S166 and S169 of endo-
genous RIPK1 in primary BMDMs arguing against insufficient
activation of RIPK1. Moreover, we could reproducibly measure the
un-phosphorylated peptide containing S161, arguing against pro-
blems with peptide detection. Together, these results question the
possible role of S161 autophosphorylation in regulating RIPK1
kinase activity-dependent functions. Further studies will be required
to experimentally validate the possible role of S161 and other RIPK1
autophosphorylation sites in regulating RIPK1-dependent func-
tions. Particularly taking into account our findings that abolishing
S166 phosphorylation could fully prevent RIPK1 kinase-dependent
cell death and inflammation in vivo, but only partially prevented
RIPK1 kinase-mediated cell death in cell culture assays, it will be
crucial to assess the role of different autophosphorylation sites in a
physiological setting by generating mouse models expressing
endogenous RIPK1 with specific mutations. It is also possible that
different sites may show functional redundancy, therefore gen-
erating mouse models with mutations of different sites in
combination would be necessary in order to unravel the mechan-
isms by which autophosphorylation regulates the activation of
RIPK1 kinase-dependent cell death.
Taken together, our results identify S166 autophosphorylation as
an essential event for the activation of RIPK1-dependent cell death
and the pathogenesis of inflammatory pathologies in vivo in rele-
vant mouse models. These findings support the important role of
S166 phosphorylation as a biomarker for RIPK1-mediated pathol-
ogies, which will be crucial in order to better stratify human patients
to identify those that are more likely to benefit from treatment with
RIPK1 inhibitors that reached phase II clinical trials24,25.
Methods
Mice. Ripk1D138N/D138N43, NemoFL54, Villin-Cre55, Alfp-Cre56 and Sharpincpdm/cpdm51
were described previously. Mice were maintained at the SPF animal facilities of the
Institute for Genetics and the CECAD Research Center of the University of Cologne,
under a 12 h light cycle, at a temperature of 22 ± 2 °C, 55 ± 5% relative humidity and
given a regular chow diet (Harlan, diet number 2918 or Prolab Isopro RMH3000
5P76) ad libitum. All animal procedures were conducted in accordance with Eur-
opean, national and institutional guidelines and protocols were approved by the
responsible local authorities (Landesamt für Natur, Umwelt und Verbraucherschutz
Nordrhein-Westfalen, Germany; ethical committee of Ghent University, Belgium).
Animals requiring medical attention were provided with appropriate care and were
sacrificed when they developed macroscopically visible skin lesions to minimize
suffering. Mice of the indicated genotype were assigned at random to groups. Mouse
studies were performed in a blinded fashion.
CRISPR/Cas9-mediated generation of Ripk1S166A/S166A mice. For the genera-
tion of Ripk1S166A/S166A mice, Cas9 mRNA (TriLink) together with the 120 bp
ssDNA repair oligo (IDT) and the short guide RNA (sgRNA) were microinjected
into the pronucleus of fertilized oocytes obtained from C57BL/6 mice. A sgRNA
targeting a site adjacent to position 166 of the murine Ripk1 gene was used (5’ GAC
ATG GAG CAA ACT GAC TA3’). On the next day, the injected embryos were
transferred to foster mothers and allowed to develop to term. Mutations in the
genome of progeny were determined by analysis of genomic DNA using the T7
endonuclease I assay (NEB) and sequencing. Sequenced DNA fragments were
aligned using Benchling [Biology Software] (2020, https://benchling.com). The
sequence of the ssDNA oligo used as repair template for the RIPK1S166A knock-in
was 5ʹ CTC TTC TTT TCC AGA TAG CCG ATC TTG GTG TGG CTT CCT TTA
AGA CAT GGG CCA AA C TGA CTA AAG AGA AAG ACA ACA AGC AGA
AAG AAG TGAG CAG CAC CAC TAA GAA GAA CAA TGG TG 3ʹ. Primers to
Fig. 5 S166 phosphorylation is essential for RIPK1-dependent skin inflammation in Sharpincpdm/cpdm mice. a Kaplan-Meier curve of lesion-free survival
of mice of the indicated genotypes. b Representative macroscopic pictures of mice of the indicated genotypes at the age of 15–17 weeks. c Representative
skin sections from mice of the indicated genotypes at the age of 15-17 weeks stained with H&E or immunostained with antibodies against cleaved caspase-
3 (CC3), keratin 6 (K6), keratin 10 (K10), keratin 14 (K14), F4/80 and DAPI (DNA stain). Scale bars in H&E and CC3 pictures 50 μm, in K6, K10/K14 and
F4/80 pictures 20 μm. d Graphs depicting relative mRNA expression of the indicated genes in RNA from whole skin tissue of mice of the indicated
genotypes at 15–17 weeks of age, measured by qRT-PCR. The dots in the graphs represent individual mice. Mean ± s.e.m. is shown for each group of mice in
all graphs. Statistical significance was determined using a Kruskal-Wallis test (one-sided). e Representative images of H&E stained tissue sections from
liver and lung from mice of the indicated genotypes at 15–17 weeks. Scale bars, 100 μm. Source data for a, d are provided as a source data file.
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amplify DNA fragments for Surveyor assay and sequencing were: (5ʹ GCA GCC
ACT GGA AAA TTG AT 3ʹ) and (5ʹ TGT CTT ACT CTC ATA GGG CTC C 3ʹ).
Histological analysis of tissue sections. Skin, colon and liver tissue samples from
mice were fixed overnight in 4% paraformaldehyde, embedded in paraffin, and cut
in 3–5 µm sections. For Immunohistochemistry staining, paraffin sections were
rehydrated and heat-induced antigen retrieval was performed in Tris-citrate buffer.
Sections were incubated with primary antibodies against cleaved caspase-3 (9661,
Cell Signaling Technology), Ki-67 (DAKO, M724901), α-SMA (Sigma-Aldrich,
A2547), F4/80 (clone A3-1, AbD Serotec), Keratin 14 (MS-115, Neomarkers),
Keratin 6 (PRB-169P, Covance) and Keratin 10 (PRB-159P, Covance). Biotinylated
secondary antibodies were purchased from Perkin Elmer, Dako and Invitrogen.
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Nuclei were stained by DAPI (VectorLabs). Stainings were visualized with ABC Kit
Vectastain Elite (Vector Laboratories) and DAB substrate (Dako and Vector
Laboratories) or Alexa-488 (A1101, Molecular Probes) and Alexa-549 (A11012,
Molecular Probes)-fluorescence-conjugated secondary antibodies. F4/80 staining
was done on cryo sections.
Histopathological scoring. Histopathological evaluation of colon tissue sections
was performed on 3 µm H&E stained intestinal tissue sections in a blinded fashion
as described previously57. In brief, inflammation was assessed by the presence and
the localization of inflammatory immune cell infiltrates (0: absent, 1: mucosal, 2:
submucosal, 3: transmural extending into muscularis and serosa, and 4: diffuse).
Fig. 7 S166 phosphorylation enhances RIPK1 kinase activity. a Scheme depicting the possible combinations of RIPK1 dimers in Ripk1D138N/S166A mice.
Residue 166 on RIPK1 is indicated. b, BMDMs from mice of the indicated genotypes were treated with a combination of TNF (T; 10 ngml−1), SMAC
mimetic (S (Birinapant), 1 μM) and Z-VAD-FMK (Z) for 0, 2 or 4 h and lysates were analyzed by immunoblot with the indicated antibodies. Blots shown
are representative of three independent experiments. *Non-specific band. c Primary lung fibroblasts from mice of the indicated genotypes were treated
with a combination of TNF (T; 20 ngml−1), SMAC mimetic (S (Birinapant), 1 μM) and Z-VAD-FMK (Z) for 0, 3 or 5 h and lysates were analyzed by
immunoblot with the indicated antibodies. Blots shown are representative of three independent experiments. d BMDMs from mice of the indicated
genotypes were treated with combinations of TNF (T; 10 ngml−1), SMAC mimetic (S (Briniapant), 1 μM) and Z-VAD-FMK (Z) in the presence or absence
of Nec-1s. Cell death was measured using IncuCyte. Graph shows mean of technical triplicates. Data are representative of three independent
experments. For purpose of comparability the data of the genotypes WT, Ripk1S166A/S166A and Ripk1D138N/D138N shown here are identical to those in Fig. 1b.
e BMDMs were treated with a combination of TNF (T; 10 ngml−1), SMAC mimetic (S (Birinapant), 1 μM) and Z-VAD-FMK (Z) for 0, 2 or 4 h. FADD
immunoprecipitates and total cell lysates (input) were analyzed by immunoblot using the indicated antibodies. f BMDMs were treated with a combination
of TNF (T; 10 ngml−1), SMAC mimetic (S (Birinapant), 1 μM) and Z-VAD-FMK (Z, 50 μM) for 0, 2 or 4 h. Caspase-8 immunoprecipitates and input were
analyzed by immunoblot using the indicated antibodies. Source data for d are provided as a source data file.
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Fig. 8 S166 phosphorylation promotes RIPK1 autophosphorylation at additional sites. a LC–MS/MS measured log2 intensities of the p-S166 p-T169- and
p-S313 sites after indicated treatment with or without a combination of TNF (10 ngml−1), SMAC mimetic ((Birinapant), 1 μM) and Z-VAD-FMK
(TSZ) for 2 h. b Selected LC–MS/MS scan of the p-S166/p-T169 RIPK1 peptide with annotated b-and y-ions. Fragment ions marked with asterisk (*) result
from loss of the phospho-group. c LC–MS/MS measured log2 intensities of RIPK1 peptides after indicated treatment with or without a combination of TNF
(10 ngml−1), SMAC mimetic ((Birinapant), 1 μM) and Z-VAD-FMK (TSZ) for 2 h. d LC–MS/MS measured log2 intensities of the RIPK1 p-S25 site after
indicated treatment with or without a combination of TNF (10 ngml−1), SMAC mimetic ((Birinapant), 1μM) and Z-VAD-FMK (TSZ) for 2 h. e LC–MS/MS
measured log2 intensities of the RIPK1 p-S14 site after indicated treatment with or without a combination of TNF (10 ngml−1), SMAC mimetic
((Birinapant), 1μM) and Z-VAD-FMK (TSZ) for 2 h. a, c–e, Values from two independent experiments are shown.
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For the evaluation of tissue damage four scores were ascribed to crypt hyperplasia,
epithelial injury and death of epithelial cells (0: absent, 1: mild, 2: moderate and 3:
severe). The sum of these inflammation or tissue damage scores were then mul-
tiplied by a factor according to the fraction of the tissue being affected: 1: < 25%; 2:
25–50%; 3: 50–70% and 4: >75%. The total histological score represents the sum of
inflammation and damage marks. Percentages of cleaved caspase-3 positive crypts
were determined by counting the number of crypts containing cleaved caspase-3
positive cells in a representative area of the section and normalizing to the total
number of crypts in that area.
Primary cell isolation and culture. Lung fibroblasts were prepared from whole lung
tissue and dermal fibroblasts were prepared from tail and ear tissue using Collagenase
Type 2 (Worthington, 44N15307B). Fibroblasts were maintained in Dulbecco’s
Modified Eagle Medium (Gibco) supplemented with Penicillin-Streptomycin, L-Glu-
tamine, Sodium Pyruvate, HEPES Buffer Solution (1% each, all Gibco) and 10% fetal
serum (PAN Biotech). BMDMs were isolated from mice according to standard
procedures and maintained in similar medium as fibroblasts, but with 10% fetal
bovine serum superior (Biochrom) and 20 ngml−1 M-CSF (Immunotools,
12343118). BMDMs were differentiated for 6 days before plating for experiments.
Immunoblotting and immunoprecipitation. Antibodies against the following
proteins were used for immunoblot analysis: p-IκBα (2859, Cell Signaling Technol-
ogy), IκBα (sc-371, Santa Cruz Biotechnology), p-p65 (3033, Cell Signaling Tech-
nology), p65 (sc-372, Santa Cruz Biotechnology), p-SAPK/JNK (T183/T185) (4668,
Cell Signaling Technology), SAPK/JNK (9252, Cell Signaling Technology), p-p38
(9211, Cell Signaling Technology), p38 (9212, Cell Signaling Technology), p-p44/42
MAPK/ERK (9191, Cell Signaling Technology), p44/42 MAPK (9102, Cell Signaling
Technology), RIPK1 (610459, BD or 3493, Cell Signaling Technology, or custom-
made rabbit anti-RIPK1 serum), p-RIPK1(S166) (31122, Cell Signaling Technology),
p-RIPK3 (57220, Cell Signaling Technology), RIPK3 (ADI-905-242-100, Enzo Life
Sciences or clone1G6.14, Genentech58 or PA5-19956, Thermo Fisher), p-MLKL
(S345; D6E3G, Cell Signaling Technology or ab196436, Abcam), MLKL (MABC604,
Millipore), caspase-8 (ALX-804-447, Alexis), FADD (05-486, upstate or sc-6036,
Santa Cruz Biotechnology or ADI-AAM-212-E, Enzo Life Scienes), TRADD
(AHP2533, Bio-Rad Laboratories), GAPDH (NB300-221, Novus Biologicals), Tubulin
(T6074, Sigma-Aldrich or ab21058, Abcam), mouse IgG HRP-linked antibody
(NA931, GE Healthcare), rabbit IgG HRP-linked antibody (NA934V, GE Healthcare)
and rat conjugated to HRP (112-035-003, Jackson Immuno Research). Signals were
detected using SuperSignal West Pico Chemiluminescent substrate (34080, Thermo
Fisher Scientific), Amersham ECL Western Blotting Detection Reagent (GE Health-
care) or SuperSignal™ West Pico PLUS Chemiluminescent Substrate (34580, Thermo
Fisher Scientific) and SuperSignal™ West Femto (34095, Thermo Fisher Scientific).
The membranes were reprobed after incubation in Restore Western Blot stripping
buffer (21059, Thermo Fisher Scientific). To check RIPK1-interacting proteins, RIPK1
was immunoprecipitated using custom-made anti-RIPK1 serum which was BS3-
crosslinked to Dynabeads™ Protein G (10009D, Invitrogen). In brief, cells were placed
on ice after treatment and cell lysates were prepared in immunoprecipitation (IP)
buffer (20mM HEPES-KOH (pH 7.6), 150mM NaCl, 2mM EDTA, 1% Triton X-
100, 10% Glycerol, cOmplete Tablets Mini (Roche, 04693124001) and PhosSTOP
(Roche, 04906837001). Crosslinked beads and serum were added to lysates and left
overnight with rotation at 4 °C. The next day, beads were washed twice in IP buffer
and immunprecipitates were eluted by boiling in Laemmli buffer. For FADD-IPs and
caspase-8 IPs, the protocol was similar, however in this case Protein G beads (Invi-
trogen for FADD IPs and 10003D, Life Technologies for caspase-8 IPs) were pre-
incubated with anti-FADD antibody (sc-6036, Santa Cruz Biotechnology) or anti-
caspase-8 custom-made serum without cross-linking and subsequently added to cell
lysates for incubation overnight. For TNFR1 complex I IPs, 8×106 BMDMs were
seeded on a 60 cm2 tissue culture plate. The next day, cells were treated with 1 µg
ml−1 FLAG-hTNF. The cells were washed two times in ice-cold PBS, followed by lysis
in NP-40 lysis buffer (10% glycerol, 1% NP-40, 150mM NaCl and 10mM Tris-HCl
pH 8 supplemented with phosphatase and protease inhibitor cocktail tablets (Roche
Diagnostics)). The cell lysates were cleared by centrifugation for 15min at 4 °C and
the supernatants were then incubated overnight with FLAG M2 affinity gel (Sigma-
Aldrich). The next day, the beads were washed three times in NP-40 lysis buffer and
FLAG-eluted using 150 ng µl−1 3X FLAG peptide for 30min at RT. The FLAG eluate
was diluted in 5x Laemmli buffer and analyzed by immunoblotting.
Cell death assays. BMDMs were seeded at 25.000 cells, dermal and lung fibroblasts
were seeded at 10.000 cells per well in a 96 well plate. The following day, cells were
pre-treated with combinations of Z-VAD-FMK (Enzo, ALX-260-020-M005, 20 μM if
not specified otherwise), Nec1s (BioVision, 2263, 20 μM), Birinapant (BioVision,
2597) in the presence of the dead cell stain YoyoTM-1 Iodide (Yoyo-1; Invitrogen,
Y3601; 0,5 μM for fibroblasts and 0,25 μM for BMDMs) for 30min, before addition of
recombinant mouse TNF (VIB Protein Service Facility, Ghent), LPS (Enzo, ALX-581-
010-L002, 100 ngml−1) or Poly (I:C) (EDM Millipore, 42424-50-0, 50 μgml−1 for
analysis of NF-κB and MAPK activation, 0.5 μgml−1 for cell death assays). Dead cells
were imaged in real-time for 24 h in intervals of 2 h via fluorescence signals using an
IncuCyte® S3 Live-Cell Analysis System (Essen Bioscience). Percentages of cell death
were calculated by treating two wells per genotype in each experiment with the cell-
permeable fluorescent stain Draq5 (Cell Signaling Technology, #4084L, 500 μM) and
imaging at a 0 h timepoint, which allows quantification of the total number of cells
present per field. Resulting images were analyzed using the software package of the
IncuCyte which allows quantification of the number of Yoyo-1 or Draq5-positive
cells. Dead cell counts acquired via Yoyo1-1 staining were divided by the total cell
number of Draq5-positive cells to yield the percentage of cell death at each timepoint.
Curves show the mean of two technical replicates.
Quantitative RT-PCR. Total RNA was extracted using Trizol Reagent (Life
Technologies) and RNeasy Columns (Qiagen) followed by cDNA preparation
using Superscript III cDNA-synthesis Kit (Life technologies). qRT-PCR was per-
formed using TaqMan probes in duplicates for each sample (Life technologies)
with Hprt or Tbp serving as reference gene. Relative expression of gene transcripts
was analyzed via the 2-ΔCt method and are presented in dot plot graphs as mRNA
expression values relative to the reference gene.
RNA isolation and microarray analysis. Colon tissues were disrupted using a
Precellys 24 (Bertin technologies) and total RNA from colon tissue was extracted
using a Nucleospin® RNA kit (Macherey-Nagel) according to manufacturer’s
instruction. 100 ng of total RNA per sample were used as input for the Clariom-S-
mouse microarray (Thermo Fisher Scientific) analysis. Target preparation was
performed using the Gene ChipTM WT PLUS Reagent Kit (Thermo Fisher Sci-
entific) according to manufacturer’s instructions. Hybridization was performed in a
Gene Chip Hybridization Oven 645 for 16 h at 45 °C. Gene chips were scanned
using the Gene Chip Scanner 7 G. The Clariom-S-mouse array was in a 169 format,
for which the Fluidics Protocol FS450-0007 was used. Array-Quality Control was
done using the Affymetrix Expression Console or Transcriptome Analysis Console
(TAC) Software. Z score transformation and heat cluster data analysis was per-
formed using InstantClue59.
TNF-induced SIRS model. For the TNF shock model, 500 µg kg−1 mTNF (diluted in
endotoxin-free PBS pH 6.8) was intravenously injected in mice. Mortality and body
temperature were monitored until 36 h after mTNF injection. Rectal body temperature
was recorded with an industrial electric thermometer (Comark Electronics, Norwich,
UK; model 2001). Mice were sacrificed when body temperature reached 25 °C.
LC–MS/MS phosphorylation analysis. Cell lysates were precipitated with acetone
and resuspended in 8 M Urea. After reduction with DTT and carbamidomethy-
lation with IAA, proteins were digested overnight at RT, using the proteases LysC
(Wako) and trypsin (Promega). Samples were desalted using SepPak C18 cartridges
(Waters) and phosphorylated peptides were enriched with the High-Select TiO2
Phosphopeptide Enrichment Kit (Thermo Fisher Scientific). Proteomic analysis
was performed using an Easy nLC 1000 UHPLC coupled to a QExactive Plus mass
spectrometer (Thermo Fisher Scientific). Peptides were resuspended in Solvent A
(0.1% FA), picked up with an autosampler and loaded onto in-house made 50 cm
fused silica columns (internal diameter (I.D.) 75 μm, C18 1.7 μm, Dr. Maisch
beads) at a flow rate of 0.75 µl min−1. A 90 min segmented gradient of 8-48%
Solvent B (80% ACN in 0.1% FA) over 61 min, 48-70% Solvent B over 6 min, and
70-95% Solvent B over 5 min at a flow rate of 250 nl min−1 was used to elute
peptides. Eluted peptides were sprayed into the heated transfer capillary of the
mass spectrometer using a nano-electrospray ion source (Thermo Fisher Scientific).
The mass spectrometer was operated in a data-dependent mode, where the
Orbitrap acquired full MS scans (300-1750m/z) at a resolution (R) of 70,000 with
an automated gain control (AGC) target of 3×106 ions collected within 20 ms. The
dynamic exclusion time was set to 20 s. From the full MS scan, the 10 most intense
peaks (z ≥ 2) were fragmented in the high-energy collision-induced dissociation
(HCD) cell. The HCD normalized collision energy was set to 25%. MS/MS scans
with an ion target of 1×106 ions were acquired with R= 17,500, with a maximal
injection time of 80 ms and an isolation width of 2.0m/z. The raw files were
processed using MaxQuant software (Version 1.5.3.8.) and its implemented
Andromeda search engine60. Minimum score for modified peptides was set to 0,
remaining parameters were set to default values and Phospho (STY) was added as
variable modification. Phosphosite intensities were logarithmized and gene ontol-
ogy annotations assigned using Perseus software61.
Statistics and reproducibility. When data fulfilled the criteria for Gaussian dis-
tribution, one-way Anova was performed; otherwise the nonparametric one-sided
Kruskal-Wallis test was chosen. Statistical analysis was performed with Prism,
GraphPad. Histological analysis was performed independently on tissue samples
from at least three animals per genotype. Specifically, in Fig. 4b: WT n= 3,
NEMOLPC-KO n= 3, NEMOLPC-KO Ripk1S166A/S166A n= 5, Ripk1S166A/S166A n= 3,
in Fig. 4d: WT n= 3, NEMOLPC-KO n= 3, NEMOLPC-KO Ripk1S166A/S166A n= 5,
Ripk1S166A/S166A n= 3 in Fig. 5c n= 5 (H&E) or n= 3 (CC3, K10/14, K6, F4/80)
per genotype and in Fig. 5e n= 3 samples per genotype were examined.
Reporting Summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
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Data availability
The microarray data discussed in this publication have been deposited in NCBI’s Gene
Expression Omnibus62 and are accessible through GEO Series accession number
GSE131855. The mass spectrometry proteomics data have been deposited to the
ProteomeXchange Consortium via the PRIDE63 partner repository with the dataset
identifier PXD014097. The source data underlying Figs. 1b–i, 3b–d, 4a, e, f, 5a, d, 6a, b,
and 7d and Supplementary Fig. 1d are provided as a Source Data file. Uncropped images
of immunoblots presented in the figures are included in “Supplementary Fig. 2”.
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